|Videos|November 17, 2022

Novel Bispecific Agents in the Treatment of Multiple Myeloma

Author(s)Rafael Fonseca, MD, Amrita Y. Krishnan, MD, Caitlin Costello, MD

Amrita Krishnan, MD, and Krina Patel, MD, review promising bispecific agents under investigation for multiple myeloma treatment.

Episodes in this series

The panel sits behind a desk, smiling at the camera.

EP. 1 Induction Regimen Options for Patients with Transplant-Eligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 2 Selecting a Treatment Regimen for Patients with Transplant-Eligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 3 Measuring Treatment Response in Transplant-Eligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 4 First-Line Treatment Options in Transplant-Ineligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 5 Treatment Regimens for Frail Patients with Transplant-Ineligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 6 Goals and Duration of Treatment for Elderly Patients with Transplant-Ineligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 7 Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma

The panel sits behind a desk, smiling at the camera.

EP. 8 Novel Bispecific Agents in the Treatment of Multiple Myeloma

The panel sits behind a desk, smiling at the camera.

EP. 9 CAR T-Cell Therapy in Multiple Myeloma Treatment

The panel sits behind a desk, smiling at the camera.

EP. 10 Unmet Needs and Future Directions in Multiple Myeloma Treatment

Recap: A Review of the Treatment Landscape in Multiple Myeloma

EP. 11 Recap: A Review of the Treatment Landscape in Multiple Myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

November 4th, 2026

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

October 29th, 2026

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

$FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma$

October 27th, 2026

FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma

Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

October 27th, 2026

Elranatamab Improves PFS vs Standard Regimens in R/R Multiple Myeloma

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

Trending on CancerNetwork

Setting Up an HDR Brachytherapy Program Amid a National Decline

Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL

Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer